Lucero
Lucero AB develops the first ready-to-use 3D cell culture product specifically designed for pharmaceutical drug development. Their key product is a cryopreserved assay-ready liver spheroid plate that enables drug developers to start testing metabolic activity, toxicity, and chemistry optimization within 24 hours of thawing, eliminating the need for culturing. The product is built for high-throughput workflows in pharma, using AI and microfluidics to ensure batch-to-batch uniformity and reliability. Lucero's platform supports early-stage ADME, tox, and PK/PD workflows, offering scalability, speed, and usability advantages over traditional spheroid culturing methods. The company has secured significant grants, filed patents for their novel QC and plate preparation methods, and is preparing for product launch in 2026, positioning itself as a leader in 3D cell culture tools for drug discovery.
Lucero
Lucero AB develops the first ready-to-use 3D cell culture product specifically designed for pharmaceutical drug development. Their key product is a cryopreserved assay-ready liver spheroid plate that enables drug developers to start testing metabolic activity, toxicity, and chemistry optimization within 24 hours of thawing, eliminating the need for culturing. The product is built for high-throughput workflows in pharma, using AI and microfluidics to ensure batch-to-batch uniformity and reliability. Lucero's platform supports early-stage ADME, tox, and PK/PD workflows, offering scalability, speed, and usability advantages over traditional spheroid culturing methods. The company has secured significant grants, filed patents for their novel QC and plate preparation methods, and is preparing for product launch in 2026, positioning itself as a leader in 3D cell culture tools for drug discovery.